

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-18 (Canceled).

19. (Currently amended) A kit comprising:  
an anti-CD2 antibody or an antigen-binding fragment thereof in a  
pharmaceutically acceptable carrier;  
and an immunosuppressive agent; and  
instructions to administer a short course of the immunosuppressive agent at a high dose.
20. (Previously presented) The kit of claim 19, wherein the anti-CD2 antibody is  
monoclonal.
21. (Previously presented) The kit of claim 19, wherein the antibody or antigen  
binding fragment comprises BTI-322.
22. (Previously presented) The kit of claim 19, wherein the anti-CD2 antibody binds  
an epitope also recognized by BTI-322.
23. (Previously presented) The kit of claim 19 wherein the immunosuppressive agent  
is selected from the group consisting of cyclosporine, FK-506, and rapamycin.
24. (New) The kit of claim 23, wherein the immunosuppressive agent is cyclosporine.

25. (New) The kit of claim 24, wherein the high dose of cyclosporine is at least 10 mg/kg/day.

26. (New) The kit of claim 25, wherein the high dose of cyclosporine is at least 15 mg/kg/day.

27. (New) The kit of claim 26, wherein the high dose of cyclosporine is an amount which results in blood levels of at least 500 ng/ml of cyclosporine.

28. (New) The kit of claim 27, wherein the high dose of cyclosporine is an amount which results in blood levels of at least 1000 ng/ml of cyclosporine.

29. (New) The kit of claim 19, wherein the short course is less than 12 days.

30. (New) The kit of claim 19, wherein the short course is about 8 to 12 days.

31. (New) The kit of claim 19, wherein the short course is about 10 days.

32. (New) The kit of claim 19, wherein the instructions provide that the short course administration of the immunosuppressive agent is administered prior to introducing a graft into a recipient mammal.

33. (New) The kit of claim 19, wherein the instructions provide that the short course administration of the immunosuppressive agent is administered at about the time the graft is introduced into a recipient mammal.

34. (New) The kit of claim 19, wherein the instructions provide that the short course administration of the immunosuppressive agent is administered after the time the graft is introduced into a recipient mammal.

35. (New) A kit comprising:  
an anti-CD2 antibody comprising BTI-322 or an antigen-binding fragment thereof in a pharmaceutically acceptable carrier;  
an immunosuppressive agent; and  
instructions to administer a short course of the immunosuppressive agent at a high dose.

36. (New) A kit comprising:  
an anti-CD2 antibody or an antigen-binding fragment wherein the anti-CD2 antibody or antigen-binding fragment thereof binds an epitope also recognized by BTI-322 thereof in a pharmaceutically acceptable carrier;  
an immunosuppressive agent; and  
instructions to administer a short course of the immunosuppressive agent at a high dose.